CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Learn the long-term average annual return for index funds and how it informs portfolio construction, diversification, and risk management.
27,739 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Once-skeptical of SaaS valuations, this longtime saas bear now highlights real value in beaten-down software. He shar...
A historic clash over openness in software mirrors today’s AI debate, with investors watching who controls code, data...
Bumble reports softer user growth and a hefty impairment bill, even as cash flow improves. The AI-driven reboot is dr...
Insider moves can spark questions for investors. This article unpacks what insider selling means, how to read Form 4 ...
BNB Chain unveils the BNBAgent SDK, the first live implementation of ERC-8183, enabling trustless, autonomous AI work...
AI chips are reshaping tech, and ARM Holdings could ride the wave as a major royalty player. This article explains wh...
A joint Accenture-Wharton study finds AI agents can scale thinking, but human governance struggles to keep pace, crea...
NVIDIA faces a pivotal test as the year winds down. Analysts debate whether price prediction: will nvidia reach $300 ...
When an insider doubles down on a falling stock, investors sit up and take notice. This article breaks down what it c...
Memory stocks look risky on the surface, yet the fundamentals are unusually strong. This article decodes what history...
An in-depth, easy-to-read analysis of Sezzle stock and its 2026 earnings trajectory. Learn the key metrics, growth dr...